The air in the clinical trial rooms hummed with anticipation as Dr. Michael Rosenbaum, a leading endocrinologist, adjusted the syringe for the 67th participant in Phase II of the retatrutide study. The peptide—a triple-agonist of GLP-1, GIP, and glucagon—had already shown promise in early trials, but this was the moment where science would either validate […]